Market Research Report
Controlled Release Cardiovascular Therapeutics
|Controlled Release Cardiovascular Therapeutics|
Published: May 9, 2022
Greystone Research Associates
Content info: 93 Pages
Delivery time: 1-2 business days
The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to drug safety and patient compliance have focused attention on formulations that can improve drug safety profiles and reduce dosing frequency. Important treatment segments for controlled release cardiovascular drugs include angina, hypertension, arrhythmias, cholesterol, and peripheral artery disease. Important growth factors for controlled release cardiovascular drugs include evolving patient demographics, environmental and lifestyle causative factors, increased public awareness of cardiovascular conditions and their associated morbidities, and expanded patient access to cardiovascular treatment services.